Oppenheimer & Co. Inc. Invests $311,000 in Pulse Biosciences, Inc. (NASDAQ:PLSE)

Oppenheimer & Co. Inc. acquired a new position in shares of Pulse Biosciences, Inc. (NASDAQ:PLSE - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 17,850 shares of the company's stock, valued at approximately $311,000.

Several other institutional investors have also recently made changes to their positions in the company. State Street Corp lifted its holdings in Pulse Biosciences by 17.8% during the third quarter. State Street Corp now owns 461,333 shares of the company's stock worth $8,092,000 after acquiring an additional 69,696 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Pulse Biosciences by 7.8% in the 3rd quarter. Geode Capital Management LLC now owns 457,165 shares of the company's stock worth $8,020,000 after buying an additional 33,200 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Pulse Biosciences by 193.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company's stock worth $2,598,000 after buying an additional 97,565 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in Pulse Biosciences during the third quarter valued at about $588,000. Finally, Barclays PLC increased its holdings in Pulse Biosciences by 361.4% during the third quarter. Barclays PLC now owns 30,306 shares of the company's stock worth $530,000 after buying an additional 23,738 shares during the last quarter. Institutional investors own 76.95% of the company's stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised shares of Pulse Biosciences to a "sell" rating in a research report on Thursday, January 2nd.

Remove Ads

Pulse Biosciences Price Performance

NASDAQ PLSE traded up $0.10 on Wednesday, hitting $17.24. 109,073 shares of the stock traded hands, compared to its average volume of 152,846. The business's fifty day moving average is $19.29 and its two-hundred day moving average is $18.33. Pulse Biosciences, Inc. has a 12 month low of $6.59 and a 12 month high of $25.00.

Insider Buying and Selling

In other Pulse Biosciences news, Director Robert W. Duggan acquired 55,256 shares of the company's stock in a transaction on Friday, December 13th. The shares were acquired at an average cost of $17.18 per share, with a total value of $949,298.08. Following the completion of the acquisition, the director now directly owns 42,328,717 shares in the company, valued at $727,207,358.06. This trade represents a 0.13 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 71.50% of the stock is currently owned by insiders.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.